Teladoc Health, Inc. (TDOC)
AI stock analysis · as of Jul 31, 2026
Loading microstructure…
Teladoc Health (TDOC) is a virtual care provider operating two segments — Integrated Care (B2B telehealth/chronic care to health plans and employers) and BetterHelp (D2C mental health). At $6.58, the stock trades near multi-year lows with a ~$1.2B market cap, 0.48x sales, and 0.89x book, reflecting a business in revenue contraction (-1.5% in 2025), sustained GAAP losses, and a badly damaged BetterHelp franchise. The core investment question: is TDOC a deep-value FCF-generating turnaround ($137M FCF, 17% FCF yield) with viable AI/insurance-reimbursement catalysts, or a structurally challenged asset facing CPOM regulation, mental health competition, and a $1.1B 2027 convert refinancing?
valuationOptically cheap at 0.48x sales, 0.89x book, and 17% FCF yield, but EV/EBITDA of 40.9x and negative earnings growth argue the market is correctly pricing structural decline, not a bargain — fair-to-cheap only if BetterHelp stabilizes.
This analysis is from Jul 31, 2026. Want the latest on TDOC, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Trades at 0.48x sales and 0.89x book with $781M cash on balance sheet — deep-value optionality if revenue merely stabilizes
- · Generates positive free cash flow ($137M in latest period = ~17% FCF yield on market cap), unusual for a company priced as distressed
- · Losses have narrowed materially: net loss shrunk from -$1.0B in 2024 to -$200M in 2025 as goodwill impairments roll off
- · 102M-member Integrated Care base provides cross-sell runway via unified Prism platform and new chronic-care/cardiometabolic programs
- · Tuck-in M&A (Catapult, Telecare Australia, UpLift) plus international/BetterHelp insurance-reimbursement rollout offer multiple shots on goal
- · Short interest at 15.6% of float with 6.25 days to cover creates squeeze potential on any positive surprise
Bear case
- · Revenue declining three years running (2023 $2.60B → 2025 $2.53B); BetterHelp cash-pay revenue eroding under CAC pressure from Grow Therapy, Headway, Rula, Spring Health, Talkspace
- · Q2 2026 earnings triggered a 24-30% single-day drop on revenue miss and lowered Q3/FY guide — news sentiment score -0.78 reflects a decisive negative shift
- · $1.1B 2027 convert refinancing looms; current 1.25% coupon will reprice materially higher at today's rates, pressuring FCF
- · Debt/equity of 77.7x and total debt ($1.04B) exceeds cash ($781M); ROE -12.4% and still burning GAAP
- · CPOM enforcement escalating (Oregon, California passed 2025; WA/ME/CT/NC considering 2026) could force restructuring of provider entity contracts
- · EV/EBITDA of 40.9x suggests the 'cheap on sales' framing overstates value once minimal EBITDA is considered
Catalysts
- · Q3 2026 earnings on Oct 28, 2026 — inflection check on BetterHelp stabilization and guidance credibility
- · BetterHelp insurance-reimbursement rollout progress — could materially extend member LTV vs. cash-pay
- · Refinancing/repricing of the $1.1B 2027 convertible notes — a clean refi would remove overhang
- · Elevated short interest (15.6% float, 6.25 DTC) sets up squeeze potential on any positive earnings or strategic surprise
- · Potential strategic action (further tuck-ins, divestiture of BetterHelp, or take-private interest) given depressed valuation
- · AI/Pulse platform commercial traction and outcomes-based contract wins in chronic care
Key risks
- · Continued BetterHelp revenue erosion accelerates and drags consolidated growth further negative
- · CPOM legislative expansion in 2026 forces costly restructuring of clinical entity relationships
- · 2027 convert refinancing at materially higher rates consumes FCF and forces dilutive equity raise
- · Loss of a top-5 Integrated Care customer given documented concentration
- · Further goodwill impairment charges if BetterHelp or Integrated Care underperform plan
- · Google/Meta ad-cost inflation continues to squeeze BetterHelp unit economics
What to watch
- · Q3 2026 earnings on Oct 28 — BetterHelp cash-pay trend and FY guide revisions
- · Any announcement on 2027 convertible refinancing terms or timing
- · Short interest trend and days-to-cover heading into the print
- · Progress metrics on BetterHelp insurance-reimbursement enrollment
- · New CPOM legislation in WA/ME/CT/NC in 2026 sessions
- · Key technical levels: 52-week low $4.40 (downside) and $9.89 high (upside resistance)
Key metrics
Price target rationale
Base $7.50 applies ~0.55x FY26 sales assuming stabilization and modest FCF-yield compression to ~14%. Bull $11 assumes BetterHelp reacceleration, clean 2027 refi, and short squeeze on ~0.75x sales. Bear $4 reflects continued revenue decline, refi dilution risk, and a re-rating to 0.30x sales / below tangible book.
On Wall Street's view (mixed): The $7.95 consensus target implies ~21% upside and looks reasonable as a base case given FCF support, but the target range ($5.50-$11.00) and post-Q2 target cuts (Canaccord to $10) reflect genuine dispersion; consensus feels slightly optimistic until BetterHelp trajectory clarifies.
Latest filing (10-K)
Teladoc is a shrinking-revenue virtual care giant trading near distressed valuations, burning cash on BetterHelp marketing, facing CPOM regulatory tightening, and betting its recovery on AI-driven chronic care outcomes and insurance reimbursement for mental health to stabilize its two struggling segments before the $1.1B 2027 convertible note comes due.
Teladoc Health is the global leader in virtual care, operating two segments: Integrated Care (B2B telehealth, chronic care, mental health, and hospital technology sold to employers, health plans, and health systems serving ~102 million U.S. members) and BetterHelp (direct-to-consumer mental health therapy via ~35,000 licensed clinicians). The company generates 83% of revenue from recurring access fees on a per-member-per-month or per-employee-per-month basis, with the remainder from visit fees, hardware, and software licenses. It completed 17.1 million telehealth visits in 2025.
What the news says · bearish
Teladoc's Q2 2026 earnings release triggered a severe single-day selloff of roughly 24-30%, driven by a revenue miss and a materially lowered Q3 and full-year outlook, particularly around the struggling BetterHelp segment where cash-pay revenue declined. Analyst price targets were cut — Canaccord Genuity lowered its target to $10 — and mixed analyst opinions reflect deep uncertainty about the company's near-term trajectory. While a handful of contrarian voices argue the stock looks cheap on a valuation basis after a 94% five-year decline, these 'value' arguments are speculative and lack near-term catalysts to support them. The dominant narrative is one of deteriorating fundamentals, guidance cuts, and eroding investor confidence in the telehealth model. Coverage is dense and concentrated on a single bad earnings event, making the bearish read highly reliable.
This analysis is from Jul 31, 2026. Markets move. Get the current read on TDOC and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.